MedTrace Logo

A Proof-of-Concept Study Evaluating LINFU™

NCT05161013 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-02-20

No results posted yet for this study

Summary

The purpose of this research study is to study a method to detect pancreatic precancer and cancer (ductal adenocarcinoma) using ultrasound technology in those who are at significantly increased risk for developing pancreatic cancer. The LINFU™ Technique is done by analysis of pancreatic fluid collected with the help of ultrasound. This is an investigational way to detect pancreatic precancers and ductal adenocarcinoma.

Conditions

  • Pancreas Adenocarcinoma
  • Dysplasia

Interventions

DIAGNOSTIC_TEST

LINFU™

A method to detect pancreatic cancer (ductal adenocarcinoma) using ultrasound technology in those who are at significantly increased risk for developing pancreatic cancer. LINFU™ involves analysis of pancreatic fluid collected.

Sponsors & Collaborators

  • Adenocyte, LLC

    lead INDUSTRY

Principal Investigators

  • Scott Corbett, MD, FASGE · Suncoast Endoscopy of Sarasota (a division of Florida Digestive Health Specialists)

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-21
Primary Completion
2023-10-01
Completion
2023-10-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05161013 on ClinicalTrials.gov